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Angiopoietin 2 regulates the transformation
and integrity of lymphatic endothelial
cell junctions
Wei Zheng,1,2 Harri Nurmi,1,2,11 Sila Appak,3,4,11 Ame´lie Sabine,5 Esther Bovay,5 Emilia A. Korhonen,2
Fabrizio Orsenigo,6,7 Marja Lohela,8 Gabriela D’Amico,2 Tanja Holopainen,2 Ching Ching Leow,9
Elisabetta Dejana,6,7 Tatiana V. Petrova,5,10 Hellmut G. Augustin,3,4 and Kari Alitalo1,2,12
1Wihuri Research Institute, 2Translational Cancer Biology Program, University of Helsinki, Helsinki 00014, Finland; 3Division
of Vascular Oncology and Metastasis, German Cancer Research Center Heidelberg, Heidelberg 69120, Germany; 4Department of
Vascular Biology and Tumor Angiogenesis, Heidelberg University, Mannheim 68167, Germany; 5Department of Oncology, Centre
Hospitalier Universitaire Vaudois, University of Lausanne, Epalinges CH-1066, Switzerland; 6FIRC Institute of Molecular Oncology,
Milan 20139, Italy; 7Department of Biotechnological and Biomolecular Sciences, University of Milan, Milan 20129, Italy; 8Biomedicum
Imaging Unit, Biomedicum Helsinki, University of Helsinki, Helsinki 00014, Finland; 9MedImmune, Gaithersburg, Maryland 20878,
USA; 10Swiss Institute for Cancer Research, E´cole Polytechnique Fe´de´rale de Lausanne, Lausanne CH-1066, Switzerland
Primitive lymphatic vessels are remodeled into functionally specialized initial and collecting lymphatics during
development. Lymphatic endothelial cell (LEC) junctions in initial lymphatics transform from a zipper-like to a
button-like pattern during collecting vessel development, but what regulates this process is largely unknown.
Angiopoietin 2 (Ang2) deficiency leads to abnormal lymphatic vessels. Here we found that an ANG2-blocking
antibody inhibited embryonic lymphangiogenesis, whereas endothelium-specific ANG2 overexpression induced
lymphatic hyperplasia. ANG2 inhibition blocked VE-cadherin phosphorylation at tyrosine residue 685 and the
concomitant formation of button-like junctions in initial lymphatics. The defective junctions were associated
with impaired lymph uptake. In collecting lymphatics, adherens junctions were disrupted, and the vessels leaked
upon ANG2 blockade or gene deletion. ANG2 inhibition also suppressed the onset of lymphatic valve formation
and subsequent valve maturation. These data identify ANG2 as the first essential regulator of the functionally
important interendothelial cell–cell junctions that form during lymphatic development.
[Keywords: angiopoietin 2; lymphatic; VE-cadherin; junction]
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Lymphatic vessels form a unidirectional vascular drainage
system that plays important roles in fluid homeostasis,
immune responses, and fat absorption (Tammela and
Alitalo 2010). Malfunction of lymphatic vessels occurs in
many pathological conditions, such as cancer, lymphedema,
and inflammatory diseases (Alitalo 2011; Schulte-Merker
et al. 2011). The mature lymphatic vascular tree has a
hierarchical structure, with different components perform-
ing distinct functions. Blind-ended initial lymphatics are the
entry sites for fluid, macromolecules, and leukocytes.
Collecting lymphatics conduct lymph from initial lym-
phatics to lymph nodes, where immune responses are
activated, and the fluid is returned to venous circulation.
Collecting lymphatics are surrounded by smooth muscle
cells (SMCs) and contain intraluminal valves, which
facilitate lymph drainage and prevent lymph backflow,
respectively. Malformation of these structures can cause
diseases. For example, defective valve formation and
ectopic SMC association with initial lymphatics lead to
lymphedema distichiasis in FOXC2 mutant patients and
Foxc2/ mice (Petrova et al. 2004).
Both initial lymphatics and collecting lymphatics are
lined by a single layer of lymphatic endothelial cells
(LECs), which are derived from venous endothelial cells
(ECs) during embryonic development (Yang and Oliver
2014). Developing LECs first form primitive intermediate
structures, which then go through a series of expansion
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and remodeling processes and finally give rise to the
mature lymphatic vascular system (Koltowska et al.
2013). During this process, primitive LECs are destined
to form different functional units of the lymphatic
system, such as the initial and the collecting lymphatics.
The LECs that constitute these two lymphatic compart-
ments differ in a number of aspects, including differential
expression of a set of genes (Norrme´n et al. 2009). Among
the differences, a prominent distinction is the pattern of
cell–cell junctions.
Initial lymphatics have button-like junctions (buttons),
whereas collecting lymphatics have zipper-like junctions
(zippers) (Baluk et al. 2007). These specialized junctions
are considered important for the entrance of lymph
through the gaps between the buttons in initial lym-
phatics and for preventing leakage from collecting lym-
phatics (Baluk et al. 2007). A recent study showed that
developing initial lymphatics in mice first have zippers,
which start to transform to buttons around birth, and
only buttons are visible in initial lymphatics at 10 wk of
age in mice (Yao et al. 2012). However, little is known
about the regulation of this transformation. Moreover, it
remains unclear whether primitive collecting lymphatics
also have zippers initially and, if so, how they are
maintained.
Lymphangiogenesis, the growth of lymphatic vessels,
is controlled by a number of growth factors, including
those of the vascular endothelial growth factor (VEGF)
family and the angiopoietin/TIE family (Zheng et al.
2014). Many of these factors also regulate angiogenesis.
Angiopoietin 1 (ANG1) and its receptor, TIE2, are critical
for blood vessel formation and vessel remodeling during
embryonic development, and deficiency of either one
results in embryonic lethality (Dumont et al. 1994; Sato
et al. 1995; Suri et al. 1996; Patan 1998; Jeansson et al.
2011). ANG2, another growth factor of the family, was first
recognized as a natural antagonist of ANG1/TIE2 signal-
ing, since transgenic overexpression of Ang2 in mouse
embryos led to a lethal phenotype similar to that of Ang1-
delected mice (Maisonpierre 1997). However, the effects
of ANG2 on blood vessels are context-dependent (Augustin
et al. 2009). In lymphatic vessels, ANG2 appears to
be only a TIE2 agonist (Gale et al. 2002; Dellinger et al.
2008). Ang2-null mice suffer from insufficient growth
of lymphatic vessels, which have abnormal morphol-
ogies and remodeling defects (Gale et al. 2002; Dellin-
ger et al. 2008). ANG2 has been suggested to destabilize
blood vessels and is associated with increased vascular
leakiness in cancer and sepsis (van der Heijden et al.
2009; Huang et al. 2010; Holopainen et al. 2012b;
Ziegler et al. 2013). However, how ANG2 affects EC
junctions in blood and lymphatic vessels is poorly un-
derstood.
In this study, we used an ANG2-blocking antibody and
genetic approaches in mice to test whether ANG2 regu-
lates specialization of the distinct patterns of LEC junc-
tions and analyzed the role of ANG2 in valve formation
and SMC recruitment. Addressing these questions will
help to understand the specialization and maturation of
functional initial and collecting lymphatics.
Results
ANG2 regulates lymphangiogenic processes during
embryonic development
To study the function of ANG2 in lymphatic develop-
ment, we used a monoclonal antibody that specifically
blocks the binding of ANG2 to TIE2 (Mazzieri et al.
2011; Leow et al. 2012). The antibody was given every
other day to pregnant female mice starting from embry-
onic day 12.5 (E12.5). Analysis of the embryos at E18.5
revealed body swelling and hemorrhages in the toes and
tails (Supplemental Fig. S1A), but these embryos sur-
vived, and the blood vessels in the skin and mesentery
appeared normal (Supplemental Figs. S1B,C, 6G,H). In
contrast, the cutaneous lymphatic vessels showed
a number of defects (Fig. 1A–I). Lymphatic vessel de-
velopment toward the linea alba in the ventral midline
was severely reduced (Fig. 1A,E), and the vessels at the
sprouting front lacked filopodia (Fig. 1B,F). Lymphatic
vessel density, circumferential expansion of the vessels,
and EC proliferation were also significantly decreased (Fig.
1C,D,G–I).
To investigate whether Ang2 overexpression would
produce effects opposite to those of ANG2 blockade, we
used an inducible genetic mouse model, the VE-cadherin-
tTA; Tet-OS-Ang2 double-transgenic (DTG) mice, to
overexpress mouse Ang2 specifically in the endothelium
(Holopainen et al. 2012b). The DTG embryos died at
E10.5 when the transgene was not suppressed by tetracy-
cline (Supplemental Fig. S1D), similar to as reported for
embryos constitutively overexpressing Ang2 (Maison-
pierre 1997). When Ang2 overexpression was induced by
stopping tetracycline administration at E10.5, the DTG
embryos were indistinguishable in appearance from their
wild-type littermates at E18.5 (data not shown), and the
blood vessels in the skin appeared normal (Supplemental
Fig. S1E–G). Although Ang2 overexpression did not in-
crease lymphatic vessel density, it increased LEC pro-
liferation and the vessel caliber (Fig. 1J,L; Supplemental
Fig. S1H,I).
Since VEGF-C is a major lymphangiogenic factor that
activates its receptor, VEGF receptor 3 (VEGFR3), on the
surface of LECs (Zheng et al. 2014), we asked whether
Ang2 overexpression could rescue some of the pheno-
types resulting from VEGFR3 blockade. Inhibition of
VEGFR3 signaling with a specific blocking antibody
(Pytowski et al. 2005) injected from E12.5 on led to an
almost complete absence of lymphatic vessels in the
ventral skin and mesentery in E18.5 embryos regardless
of whether they were wild type or Ang2-overexpressing
(data not shown). When the VEGFR3-blocking antibody
was injected at E14.5 into wild-type females and the
ventral skin of the embryos was analyzed at E18.5, the
lymphatic vessel density and caliber were reduced (Fig.
1J–L). ANG2 overexpression did not rescue the reduced
vessel density but restored the number of LECs per
vessel length and the vessel caliber to levels comparable
with those of the control antibody-treated wild-type
embryos (Fig. 1J–L). These data suggest that ANG2 can
partially rescue the lack of VEGFC/VEGFR3 signaling,
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which further corroborates its role as a lymphangiogenic
factor.
ANG2 is required for maturation of endothelial
cell–cell junctions in initial lymphatics
LEC junctions undergo a gradual transformation from
zippers to buttons around birth in the initial lymphatics
of the trachea and diaphragm (Yao et al. 2012). We found
that the VE-cadherin-positive adherens junctions in the
dermal initial lymphatics also transformed from zippers to
buttons, although at an earlier time point, around E16.5
(Supplemental Fig. S2A, arrowheads and arrows). To un-
derstand whether ANG2 regulates this transformation
process, we treated pregnant females with the ANG2-
blocking antibody starting from E12.5, before the trans-
formation occurs, and analyzed the embryos at E18.5. At
the sprouting vessel front, junctions in the IgG-treated
lymphatics were zippers (Fig. 2A,B), consistent with the
junctional pattern at the sprouting front reported else-
where (Baluk et al. 2007; Yao et al. 2012), and ANG2
blockade did not affect this pattern (Fig. 2C,D). In the IgG-
treated initial lymphatics behind the sprouts, the LEC
shape was less elongated, and the junctions were clearly
button-like (Fig. 2E,F). Strikingly, ANG2 inhibition sup-
pressed essentially all button formation (Fig. 2G,H).
Dexamethasone has been reported to promote preco-
cious button formation (Yao et al. 2012). We asked whether
such promotion is sufficient for the transformationwithout
ANG2 activity. Whereas dexamethasone treatment of
pregnant females fromE12.5 to E18.5 resulted in prominent
button formation, including in the sprouting vessel front
(Fig. 2I,J,M,N), anti-ANG2 treatment for the same period
inhibited the button formation also in the dexamethasone-
treated vessels (Fig. 2K,L,O,P). Thus, ANG2 is indispens-
able for the zipper-to-button remodeling of LEC junctions.
Figure 1. ANG2 regulates lymphangiogenesis during
embryonic development. (A–H) Pregnant females were
injected intraperitoneally (i.p.) with 30 mg/kg ANG2-
blocking antibody or a control antibody at E12.5, E14.5,
and E16.5, and the ventral skin of embryos was ana-
lyzed at E18.5 by immunofluorescence for LYVE1,
VEGFR3, Ki67, and PROX1, as indicated. Dashed lines
indicate the umbilicus. Vessels inside the red squares
are quantified in I. (Yellow arrows) Sprouts; (white
arrows) Ki67+ LECs; (arrowheads) Ki67 LECs. Bars:
A,E, 200 mm; B,C,F,G, 20 mm; D,H, 10 mm. (I) Quanti-
fication of the migration, branch points, and sprouts;
the number of LECs per 1-mm vessel; and the percent-
age of Ki67+ LECs out of all LECs. N = 4–5. (J–L) The
mothers of VE-cadherin-tTA; TetO-Ang2 embryos were
provided with tetracycline water until E10.5, and the
ventral skin of the embryos was analyzed at E18.5. The
anti-VEGFR3 antibody (30 mg/kg) was injected i.p. at
E14.5 and E16.5. (DTG) Double transgenic for VE-
cadherin-tTA and TetO-Ang2; (Ctrl) control embryos
(wild type [WT] or single transgenic). N = 4–7. Boxed
regions are magnified in the bottom panel. Bars: top
panel, 200 mm; bottom panel, 20 mm. All values are
mean 6 SEM. (*) P < 0.05; (**) P < 0.01; (***) P < 0.001.
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When the LEC junctions of initial lymphatics had
already transformed into buttons after birth, the ANG2-
blocking antibody could not revert the buttons back to
zippers (Supplemental Fig. S2B), suggesting that ANG2 is
needed for the junction remodeling but dispensable for the
maintenance of the already remodeled junctions. In addi-
tion, overexpression of ANG2 did not seem to affect LEC
junctions (Supplemental Fig. S2C).
Genetic deletion of Ang2 suppresses junctional
maturation in initial lymphatics
To validate the results obtained with the ANG2-blocking
antibody, we also analyzed the initial lymphatics in Ang2
gene-deleted (/) mice (Gale et al. 2002; Fiedler et al.
2006). In agreement with the results of the blocking anti-
body experiment, the zipper-to-button junctional trans-
formation was also reduced in the diaphragm of Ang2/
neonates at postnatal day 5 (P5) (Fig. 3A). This suggests that
the requirement of ANG2 for the maturation of LEC junc-
tions in initial lymphatics is not restricted to the skin but
is more general.
We next checkedwhether the defective junctions persist
in adult mice. In 10-wk-old wild-type mice, lymphatic
vessels have become quiescent without any sprouts in the
initial lymphatics, including the sprouting vessel front,
where LEC junctions are mostly buttons (Yao et al. 2012).
In our analysis of 8-wk-old wild-type mice, 64% of the
junctions were made of mature buttons, whereas in the
Ang2-deleted littermates, mature buttons made up only
17%of the junctions (Fig. 3B–K; Supplemental Fig. S2D–F).
Concurrent with the defective junctions, distribution of
the lymphatic endothelial hyaluronan receptor LYVE1was
also abnormal: It was diffuse in the LECs of the zipper
pattern or concentrated at the cell–cell borders at the
transforming stage, in contrast to the high levels in the
LEC flaps of mature initial lymphatics (Fig. 3C,F,J, arrows,
arrowheads, and empty arrows, respectively). Although
compensatory mechanisms may thus exist to induce
partial transformation of the junctions eventually, the role
of Ang2 in this process is substantial.
Lymphatic uptake is impaired in embryos upon ANG2
inhibition
Since the anti-ANG2-treated embryos appeared swollen
(Supplemental Fig. S1A) and Ang2/ mice develop pe-
ripheral lymphedema (Gale et al. 2002), we tested whether
the defective junctions would compromise lymphatic
uptake. A fluorescent tracer injected into the periorbital
dermis and footpads was readily drained by the lymphatic
vessels in the IgG-treated embryos (Fig. 4A–C) but not in
any of the 11 anti-ANG2-treated embryos analyzed at
E19.5 (Fig. 4D–F). These results suggest that the failure to
transform into button-like junctions in initial lymphatics
contributes to impaired lymph uptake.
ANG2 blockade inhibits VE-cadherin phosphorylation
at Y685 while arresting the transformation into button-
like junctions
Phosphorylation of the tyrosine residue 685 (P-Y685) of
VE-cadherin has been implicated in VE-cadherin destabi-
lization and increased vascular permeability (Dejana et al.
2008; Vestweber et al. 2009; Orsenigo et al. 2012). To
determine whether VE-cadherin phosphorylation at this
site is regulated by ANG2 in initial lymphatics, we stained
the anti-ANG2- and IgG-treated embryos with an an-
tibody that specifically recognizes VE-cadherin P-Y685
(Orsenigo et al. 2012). Most of the VE-cadherin in both
LEC zippers and buttons appeared phosphorylated at Y685
in the IgG-treated skin (Fig. 5A–C,G–I,M; Supplemental Fig.
S3A). In striking contrast, little P-Y685 was detected in VE-
cadherin in the lymphatic vessels of the anti-ANG2-treated
embryos (Fig. 5D–F,J–M; Supplemental Fig. S3A), and the
VE-cadherin P-Y685-negative junctions failed to undergo
zipper-to-button transformation at the same time (Fig. 5K).
In adult mice, VE-cadherin is phosphorylated at Y685
in veins but not in arteries (Orsenigo et al. 2012). We
observed that arterial VE-cadherin was also phosphory-
lated at Y685 during embryonic development (Supplemen-
tal Fig. S3A,B). However, ANG2 blockade did not alter
VE-cadherin P-Y685 in the arteries, veins, or blood
Figure 2. ANG2-inhibited embryos fail to form button-like
junctions in initial lymphatics. (A–H) Pregnant females were
treated with the ANG2-blocking or a control antibody at E12.5,
E14.5, and E16.5, and the ventral skin of embryos was analyzed
at E18.5. N = 15–16 from five independent experiments. (I–P)
Females were treated with the indicated antibodies as above
together with 1 mg/kg dexamethasone. N = 4. Boxed regions in
A–G and I–O are magnified in the panels below them. (Arrows)
Zippers; (arrowheads) buttons.
ANG2 regulates LEC junctions
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capillaries (Supplemental Fig. S3A [arrows], B), which
indicates that ANG2 regulates Y685 phosphorylation
only in embryonic lymphatic vessels.
Inhibition of ANG2 results in abnormal collecting
vessel structure in embryos
To extend the analysis of ANG2 functions to collecting
lymphatics, we stained mesenteric lymphatic vessels for
VE-cadherin at different developmental stages. The LEC
junctions at E14.5–E18.5 were zippers, as in mature col-
lecting lymphatics (Supplemental Fig. S4A). The IgG-
treated collecting lymphatics, when analyzed at E18.5,
were stretched and multicellular, with an elongated EC
shape (Supplemental Fig. S4B–E). In contrast, the anti-
ANG2-treated collecting lymphatics were either imma-
ture, with very few LECs across the vessel diameter
(Supplemental Fig. S4F–I,N), or loose and ragged, with
a rounded cell shapemimicking that of the LECs in initial
lymphatics (Supplemental Fig. S4J–M). In addition, few
lymphatic valves were found (Supplemental Fig. S4E,I,M),
consistent with the findings in Ang2/ mice (Dellinger
et al. 2008). The integrity of the adherens (zipper)
junctions and their phosphorylation at Y685, however,
appeared unaltered at this stage (Supplemental Fig.
S4B,C,F,G,J,K). Neither dexamethasone nor ANG2 over-
expression changed the pattern of junctions in the mesen-
teric collecting lymphatics (Supplemental Fig. S4O,P).
ANG2 maintains the integrity of the collecting
lymphatics during postnatal development
We then examined whether ANG2 regulates LEC junc-
tions in collecting lymphatics during postnatal develop-
ment. Similar to constitutive Ang2 deletion (Gale et al.
2002; Dellinger et al. 2008), postnatal ANG2 inhibition
with the blocking antibody also induced chylous ascites
in nine out of 32 P5 pups (Supplemental Fig. S5A), and
essentially all of the anti-ANG2-treated neonates showed
chyle leakage into the mesentery (Fig. 6A–D). Further-
more, the LEC morphology in the collecting lymphatics
became rounded, and the junctions were disrupted, with
a jagged shape and breaks of zipper continuity (Fig. 6E–H).
To corroborate these data, we also analyzed the LEC
junctions in the collecting lymphatics of Ang2/mice. In
the mesentery of Ang2/ pups, the junctions were simi-
larly disrupted (Fig. 6I; Supplemental Fig. S5B). In the ear
skin of 8-wk-old mice, the junctions in the collecting
lymphatics were also disrupted; in some cases, they even
resembled the button pattern (Fig. 6J–O; Supplemental Fig.
S5C–E). Interestingly, these abnormal collecting lym-
phatics did not down-regulate LYVE1 (Fig. 6M–O), which
indicates that their maturation was impaired. In line with
the loss of integrity of the adherens junctions, FITC-
dextran leaked out from the collecting lymphatics in the
Figure 3. Ang2 gene deletion impairs the zipper-to-button junc-
tional transformation in initial lymphatics. (A) The diaphragms of
Ang2/ or wild-type (WT) P5 pups were whole-mount-stained.
(Arrows) Sprouting front. Boxed regions are magnified in the left
panel. N = 4–5. (B–K) The ear skin of 8-wk-old Ang2/ mice
(B–G) and their wild-type littermates (H–J) was whole-mount-
stained. (Arrows) Zippers; (arrowheads) transforming junctions;
(empty arrowheads) buttons. (K) Quantification of 36–43 initial
lymphatics from four mice of each genotype, analyzed for their
junctional patterns. (***) P < 0.001. Bars, 20 mm in all.
Figure 4. Defective lymph uptake in anti-ANG2-treated
embryos. Pregnant females were treated with IgG (A–C) or
the ANG2-blocking antibody (D–F) at E12.5, E14.5, and E17.5.
At E19.5, the embryos were injected with FITC-Dextran in the
periorbital dermis (arrows in A,D) or forelimb footpad (arrow-
heads in A,D) and imaged to check the tracer uptake by
lymphatic vessels. (B,C) Arrows indicate the tracer drained
by the lymphatic vessels in the IgG-treated embryos (12 of
13). (E,F) No tracer uptake was observed in the anti-ANG2-
treated embryos (N = 11). (*) Injection sites. Bars: A,D, 2 mm;
B,C,E,F, 1 mm.
Zheng et al.
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central parts of the Ang2/ ears after it was injected into
the ear tips and collected by the surrounding initial
lymphatics (Fig. 6P). Furthermore, Evans blue dye injected
intradermally into the footpads of Ang2/ mice was
drained less efficiently via the lymphatic system into the
blood circulation (Fig. 6Q). Given that the EC junctions are
defective in both the initial lymphatics and collecting
lymphatics, the compromised draining capacitymay result
from a combination of defects in the uptake by the initial
lymphatics and leakage by the collecting lymphatics.
ANG2 is required for valve formation and maturation
Lymphatic valves start to form at about E16 (Norrme´n
et al. 2009). The FOXC2 transcription factor is essen-
tial for valve formation, in cooperation with PROX1,
a transcription factor critical for the commitment to LEC
identity (Wigle and Oliver 1999; Petrova et al. 2004;
Norrme´n et al. 2009; Sabine et al. 2012). Since few valves
form in the absence of ANG2 (Supplemental Fig. S4I,M;
Dellinger et al. 2008), we examined whether ANG2
regulates valve formation via these two transcription
factors. In the IgG-treated embryos at E18.5, FOXC2 and
PROX1 were highly expressed at valves and were
expressed at lower levels in lymphangions (segments
between the valves) (Fig. 7A–C). When ANG2was blocked
starting from E12.5 and the embryos were analyzed at
E18.5, FOXC2 was almost completely absent from the
lymphatic vessels but not from the arteries (Fig. 7D–G). In
contrast, PROX1was uniformly and highly expressed in all
LECs (Fig. 7E), resembling the pattern seen in the primitive
collecting lymphatics at E14.5 (Supplemental Fig. S4A;
Norrme´n et al. 2009).
We next asked whether the suppression of FOXC2 was
a direct effect of ANG2 blockade or secondary to the
failed valve formation. FOXC2 expression in lymphatic
vessels starts at E14.5, peaks at E15.5, and decreases in
lymphangions at E17.5 (Norrme´n et al. 2009). Thus, we
examined whether ANG2 blockade inhibits FOXC2 ex-
pression at E15.5, when FOXC2 expression is highly and
uniformly expressed by all LECs, just before valve forma-
tion. At this time point, although the LECs formed thin
vessels containing only a few circumferentially organized
cells, which indicated the inhibitory effect of ANG2
blockade, FOXC2 expression in the LECs was not altered
(Supplemental Fig. S6A,B). These results indicate that
ANG2 does not control the initiation of valve forma-
tion through FOXC2 expression. Instead, it seems to be
required for the maintenance of FOXC2 expression in the
prospective valve-forming LECs and for PROX1 down-
regulation in prospective lymphangion-forming LECs.
Subsequently, we analyzed the anti-ANG2-sensitive
periods in lymphatic valve formation. Administration of
the ANG2-blocking antibody starting at E14.5, right
before valve formation, suppressed valve formation,
similar to the treatment starting at E12.5 (Fig. 7H).
Thus, ANG2 likely has a direct effect on the initiation
of valve formation. At E15–E16 during normal develop-
ment, clusters of LECs that express abundant PROX1
and FOXC2 are selected to undergo valve morphogene-
sis (Bazigou et al. 2009; Norrme´n et al. 2009; Sabine et al.
2012). These lymphatic valve-forming cells (LVCs) re-
orientate, migrate into the lumen, coalesce, form a ring-
shaped constriction, and then further extend valve
leaflets in a V shape during E16–E18.5. We therefore
blocked ANG2 starting at E15.5, when valve formation
had just begun, and analyzed the valves at E18.5. This
treatment did not block the occurrence of LVCs (Fig. 7I–
N). However, 53% of the LVCs failed to reorient and
express integrin-a9 (a valve leaflet marker) (Fig. 7I–L,Q,
termed stage 1 here; Bazigou et al. 2009), 32% were
arrested at the ‘‘ring-shape’’ stage (Fig. 7M–N,Q, stage 2),
and only 15% matured to the V-shape stage (Fig. 7Q,
stage 3), in contrast to the 66% at stage 3 in the IgG-
treated vessels (Fig. 7O–Q). On the other hand, the IgG-
treated vessels had <5% of stage 1 valves, compared with
Figure 5. ANG2 is required for VE-cadherin Y685 phosphory-
lation in developing initial lymphatics. Pregnant females were
treated with the control antibody (A–C,G–I) or the ANG2-
blocking antibody (D–F,J–L) at E12.5, E14.5, and E16.5, and the
ventral skin from the embryos was analyzed at E18.5. Bars, 20
mm. (M) Quantification of the intensities of VE-cadherin P-Y685-
positive pixels out of those of the total VE-cadherin-positive
pixels. N = 6, pooled from two independent experiments with
consistent results. (***) P < 0.001.
ANG2 regulates LEC junctions
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the 53% in the anti-ANG2-treated embryos (Fig. 7Q). After
birth, inhibition of ANG2 did not affect the already formed
valves (Fig. 6G,H, arrows). These data indicate that ANG2
is indispensable before and during valve morphogenesis
but unnecessary when the valves have matured.
ANG2 is important for proper SMC recruitment
SMCs have been shown to ectopically cover initial
lymphatics in the Ang2/ mice (Dellinger et al. 2008).
This ectopic SMC coverage was also observed in the anti-
ANG2-treated embryos in this study (Supplemental Fig.
S7A–H). Since PDGFB is an important chemoattractant for
mural cell recruitment to blood vessels (Betsholtz 2004),
we considered the possibility that ANG2 inhibition leads
to aberrant expression of PDGFB, which attracts SMCs to
the initial lymphatics. To evaluate PDGFB expression, we
used PDGFB-EGFP reporter mice (Claxton et al. 2008).
Surprisingly, little PDGFB expression was detected in the
initial lymphatics of anti-ANG2-treated embryos analyzed
at E18.5 despite the SMCcoating (Supplemental Fig. S7E–H).
On the other hand, the collecting lymphatics in the anti-
ANG2-treated embryos had only few SMCs even though
PDGFB was expressed at levels apparently similar to
those in the control embryos (Supplemental Fig. S7I–P).
Thus, PDGFB does not seem to be responsible for the
aberrant SMC recruitment induced by ANG2 inhibition.
Discussion
Unlike ANG1, ANG2 has been considered to be a context-
dependent and somewhat elusive EC growth factor for
Figure 6. Disruption of adherens junctions in
the collecting lymphatics of anti-ANG2-treated
and Ang2/ mice. (A–D) Neonatal mice were
injected with IgG or the anti-ANG2 antibody
every other day starting from P0 and were
analyzed at P5. (Arrows) Leak of chyle; (arrow-
heads) normal drainage of chyle by the collecting
lymphatics. (E–H) Whole-mount staining of
the mesenteries in A and B for VEGFR3, VE-
cadherin, and PROX1. (Arrowheads) Disrupted
interendothelial junctions; (arrows) valves. Boxed
regions are magnified in E and F. N = 7–9, two
independent experiments. (I) Whole-mount
staining of the mesentery of Ang2/ or wild-
type (WT) pups at P5. (Arrowheads) Disrupted
junctions. (J–O) Collecting lymphatics in the ear
skin of 8-wk-old Ang2/ and wild-type litter-
mate mice. (Arrows) Zippers; (arrowheads) dis-
rupted junctions; (empty arrowheads) button
junctions. N = 4–5. (P) FITC-Dextran lymphangi-
ography of wild-type and Ang2/ ears. Note the
leaked tracer, as indicated by asterisks. N = 6. (Q)
Evans Blue content in the footpad and in blood
circulation after intradermal injection in the lower
limbs. N = 6. (***) P < 0.001. Bars: A,B, 2 mm;
C,D, 0.5 mm; E,F,I–O, 20 mm; G,H,P, 100 mm.
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almost two decades. Little progress has been made in terms
of its role in lymphangiogenesis during the past 7 years. In
this study, we uncovered a novel function of ANG2 in the
patterningof specialized lymphatic endothelial cell–cell junc-
tions. In addition, ANG2 is required for initiation of lym-
phatic valve formation and their subsequent maturation and
ensures appropriate SMC recruitment to lymphatic vessels.
ANG2 has been suggested to act as a lymphangiogenic
factor, as its gene deletion leads to lymphatic hypoplasia in
mice (Gale et al. 2002; Dellinger et al. 2008). In agreement
with this view, we found that the ANG2-blocking anti-
body interfered with lymphatic vessel sprouting and LEC
proliferation. The gain-of-function approach that we used
in this study further corroborated the lymphangiogenic
Figure 7. ANG2 regulates various steps of valve morphogenesis. (A–F) Pregnant mice were treated with the indicated antibodies every
other day starting at E12.5, and the mesenteries were analyzed at E18.5. N = 3–4. (Arrows) Valves; (arrowheads) FOXC2+ ECs in the
arteries. Lymphatic vessels are outlined by dashed lines (a). Boxed regions are magnified in the corresponding insets. Bars, 20 mm. (G)
Quantification of A–F. Mean 6 SEM. (**) P < 0.01. (H) Pregnant mice were treated with the indicated antibodies from E14.5 to E18.5.
Bars: top panel, 100 mm; bottom panel, 20 mm. Boxed regions are magnified below. (Arrow) Valve. Bars: top panel, 100 mm; bottom panel,
20 mm. (I–P) Pregnant mice were treated with the indicated antibodies from E15.5 to E18.5. (Arrowheads) Clusters of lymphatic valve-
forming cells that failed to reorientate, express integrin-a9, and form valve leaflets; (open arrowheads) ‘‘ring-shaped’’ valves that
expressed integrin-a9 but did not elongate leaflets; (arrows) mature valves with elongated leaflets. (Q) Evaluation and quantification of
valve maturation in I–P. Thirty-two to 44 valves were analyzed from three to four embryos of each antibody treatment. (***) P < 0.001.
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role of Ang2. The lymphangiogenic activity seems to
partially overlap with that of VEGF-C, as ANG2 over-
expression rescued the decreased LEC proliferation but not
the reduced vessel sprouting/branching that resulted from
VEGFR3 blockade. In addition, the lymphangiogenic role
of ANG2 contrasts with its context-dependent roles in
angiogenesis. ANG2 has been shown to induce EC prolif-
eration in the presence of high VEGF but apoptosis of
ECs and vessel regression when VEGF is absent (Holash
et al. 1999; Lobov et al. 2002). This analogy does not seem
to apply to ANG2 and VEGF-C in lymphangiogenesis,
as ANG2 overexpression did not exacerbate but partially
rescued the reduced lymphangiogenesis induced by
VEGFR-3 blockade. It remains to be defined by which
mechanism ANG2 exerts its lymphangiogenic function
during development.
A key finding of this study is that ANG2 is essential for
the transformation of zipper-like junctions into a button-
like pattern in initial lymphatics. This transformation is
functionally important, as the button pattern allows an
easy fluid drainage and leukocyte entry from surrounding
tissues through the openings of endothelial flaps without
the need to frequently open and close the adherens
junctions (Baluk et al. 2007). Thus, it is likely that
impaired button formation in initial lymphatics underlies,
at least in part, the edema, swelling, and compromised
fluid-draining capacity observed in anti-ANG2-treated and
Ang2/ mice by us and others (Dellinger et al. 2008).
Concomitantly with the failed transformation into
buttons, phosphorylation of VE-cadherin Y685 was also
inhibited by ANG2 blockade. Phosphorylation of this site
has been linked to destabilization of the cell–cell junctions
in blood vessels (Wallez et al. 2006; Dejana et al. 2008;
Vestweber et al. 2009). Given that this phosphorylation is
required for VE-cadherin internalization and degradation
in response to vessel-permeabilizing agents (Orsenigo et al.
2012), it is possible that in lymphatic vessels, the ANG2-
dependent phosphorylation of VE-cadherin contributes to
the dynamic change of the junctional patterns. However,
a causal link between the phosphorylation and the trans-
formation of VE-cadherin remains to be determined.
Another important finding of our study is that ANG2
also regulates LEC junctions in collecting lymphatics by
maintaining junctional integrity. Chylous ascites has
been reported inAng2/ pups (Gale et al. 2002; Dellinger
et al. 2008) andwas also observed in the blocking antibody-
treated neonatal mice in this study. Since zipper-like
adherens junctions in collecting lymphatics ensure that
lymph fluid within the vessel lumen does not leak out
(Baluk et al. 2007), it is likely that the disrupted junctions
upon ANG2 blockade or gene deletion contribute to the
observed chylous ascites and leakage. The collecting
lymphatics of Ang2/ mice are found to exhibit an oak
leaf cell shape, which is characteristic of the LECs in initial
lymphatics (Dellinger et al. 2008). Notably, the regulation
of junctional integrity in collecting lymphatics seems to be
a distinct function of ANG2, as conditional deletion of
Vegfc did not alter the junctions in collecting lymphatics
(H Nurmi, P Saharinen, W Zheng, and K Alitalo, unpubl.).
These results indicate that ANG2 has more specific
functions than being just a general growth factor for cell
proliferation and migration.
Although ANG2 has been implicated in blood vascular
leakage in a number of disease models (van der Heijden
et al. 2009; Huang et al. 2010), little evidence has directly
attributed the blood vessel leakage to junctional failure. We
did not detect changes of the phosphorylation or the pattern
of VE-cadherin in blood vessels during development. In-
stead, our results indicate a prominent regulatory role for
ANG2 in the EC junctions in developing lymphatic vessels.
The sensitivity of LEC junctions to ANG2 blockade
was dependent on the developmental phase. In postnatal
mice, when zippers had largely transformed to button junc-
tions, the anti-ANG2 treatment could no longer revert
them. In adult mice, the sensitivity was further decreased,
and no apparent phenotypes were observed upon anti-
ANG2 treatment for 6 d (data not shown). For comparison,
mice appeared normal also when VEGF was blocked 4 wk
after birth (Gerber et al. 1999) or when Ang1 was deleted
after E13.5 (Jeansson et al. 2011). However, we cannot
exclude the possibility that ANG2 contributes to lym-
phatic vessel function in pathological conditions in adult
mice, as has been reported for ANG1 in response to injuries
(Jeansson et al. 2011; Lee et al. 2013).
Lymphatic valves are absent from the Ang2/ neona-
tal mice (Dellinger et al. 2008). Our results advance the
understanding of this defect by showing that ANG2 is
necessary for the formation and maturation of valves but
not their maintenance. Recent studies have uncovered a
number of valve-regulating genes, including Foxc2 and
Prox1 (Schulte-Merker et al. 2011). However, ANG2 did
not seem to initiate valve formation directly via regulation
of FOXC2. Instead, ANG2-dependent valve formation was
required to maintain FOXC2 expression in the forming
valves. Otherwise, FOXC2 expression was globally turned
down throughout collecting lymphatics, possibly via the
same intrinsic mechanisms that down-regulate FOXC2
expression in lymphangions. Furthermore, PROX1, which
is down-regulated inwild-type lymphangions at E18.5, was
uniformly and highly expressed throughout the collecting
lymphatics. The lack of PROX1 down-regulation may
impair the selection of valve-forming cells. Furthermore,
the impaired lymphatic drainage in the skin suggests
decreased lymph flow in the collecting lymphatics, partic-
ularly when these collecting lymphatics did not seem to
have functional lumens at E18.5. Since recirculating
lymph flow has been suggested to induce valve formation
(Sabine et al. 2012), the lack of lymph flow might indi-
rectly contribute to the observed valve agenesis.
Taken together, our data suggest that ANG2 has a pre-
viously unappreciated role in the formation of specialized
LEC subsets (Supplemental Fig. S8). Without ANG2,
the LECs exhibit a mixture of phenotypes. In initial
lymphatics, LECs failed to acquire some typical features,
such as the button pattern of LEC junctions, but ectop-
ically recruit SMCs. In prospective lymphangions, on the
other hand, the LECs failed to down-regulate LYVE1 and
PROX1while losing intact zipper-like junctions and SMC
association. Moreover, insufficient numbers of LECs
were activated to form valves. This mixed phenotype
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model also explains why the impaired button formation
in initial lymphatics was partially restored in adult mice,
whereas zippers in the collecting lymphatics were dis-
rupted. In this regard, ANG2 seems to have a different
role than the Notch pathway, which preferentially spec-
ifies cell fates in lymphangiogenesis (Zheng et al. 2011). It
remains to be identified in future work whether LECs
themselves are the only cellular source of ANG2, how
ANG2 expression is distributed in lymphatic vessels,
why ANG2 loss of function has more prominent effects
on lymphatic vessels than on blood vessels during de-
velopment, how ANG2 exerts its multiple functions, and
how its activity is modulated by other regulators.
In conclusion, ANG2 is essential for appropriate pattern-
ing of LEC junctions at distinct compartments of a lym-
phatic vessel. Formation of buttons in initial lymphatics
and maintenance of zippers in collecting lymphatics are
functionally important, as they provide efficient fluid
uptake by permeable initial lymphatics and delivery by
nonleaky collecting lymphatics. While previous research
has focused on the acquisition of valves to evaluate
lymphatic vessel maturation, our results add another
parameter by analyzing the junctional transformation in
initial lymphatics. Knowledge of the effects of ANG2 on
the function of the lymphatic drainage is important for
therapeutic use of ANG2 antagonists in cancer and possi-
bly in sepsis. Our findings should also provide a new basis
for studies of other molecules involved in the process of
junctional patterning as well as mechanisms that select for
LECs that form different anatomic structures.
Materials and methods
Transgenic and knockout animals
The VE-cadherin-tTA (TET-Off) driver mice where generously
provided by Dr. Laura Benjamin (Sun et al. 2005). The TetO-
Ang2 responder has been previously described in detail (Holopai-
nen et al. 2012b) andwas backcrossed to C57Bl/6J for at least seven
generations in this study. The driver and responder transgenic
mouse lines were crossed to obtain DTG VE-cadherin;TetO-Ang2
offspring. Ang2 expression in DTG embryos was repressed by 2
mg/mL tetracycline (Sigma-Aldrich) in 5% sucrose in the drinking
water for the pregnant females, starting within 2 d post-coitum,
until Ang2 expression was induced by discontinuing tetracycline
administration. The tetracycline-containing water was changed
every 2–3 d. Single transgenic orwild-type littermateswere used as
controls for DTG mice or embryos. Ang2/ mice were bred as
previously reported (Gale et al. 2002; Fiedler et al. 2006). Eight-
week-old male mice or P5 pups were analyzed for their LEC
junctions. The Pdgfb-Cre-EGFP mice have been previously de-
scribed (Claxton et al. 2008). PDGFBwas visualized by staining for
EGFP. The embryonic time points were determined according to
vaginal plugs. The Committee for Animal Experiments of the
District of Southern Finland approved all animal experiments.
Antibody inhibition to study developing lymphatic vessels
For the study of embryos, pregnant C57Bl/6J females were in-
jected intraperitoneally (i.p.) with the ANG2-blocking antibody
(Mazzieri et al. 2011; Leow et al. 2012), the anti-VEGFR3 antibody
(Pytowski et al. 2005), or human immunoglobulin G (Sigma-
Aldrich) as a control every other day at 30 mg/kg for the time
periods indicated in the figure legends. For the study of neonatal
mice, pups of NMRI background were injected subcutaneously in
the back with 30 mg/kg anti-ANG2 or hIgG every other day
starting at P0 and were analyzed at P5. Dexamethasone (1 mg/kg;
Sigma-Aldrich, #D2915) was injected i.p. into pregnant mice daily
starting from E12.5 until E18.5 in combinationwith the anti-Ang2
antibody or hIgG, which were injected at E12.5, E14.5, and E16.5.
Lymphangiography
In embryos, 1–2 mL of 10 mg/mL FITC-Dextran (2000 kD; Sigma-
Aldrich) was injected into the periorbital dermis or the forelimb
footpads at E19.5 (Sabine et al. 2012). One minute after the
injection, the embryos were imaged for 10–15 min with a stereo-
microscope (Leica, M205FA). Embryo viability wasmonitored by
observing fetal breathing movements (12 of 14 for the control
and 11 of 12 of anti-Ang2 antibody treatments).
In adult mice, 5 mL of 25% FITC-Dextran (2,000,000 kDa;
Sigma) was injected intradermally into the ear rim, and the central
region of the earwas imaged immediately using theOlympus IX81
inverted microscope. Alternatively, 40 mL of 2% Evans Blue (in
PBS) was injected into the right hindlimb footpad. After 30 min,
themice were euthanized, Evans Blue content was ana-lyzed from
500 mL of venous blood, and the injected footpad was extracted in
formamide for 48 h at 56°C. The optical intensity of the dye was
measured at 620 nm with a spectrophotometer.
Immunofluorescent staining and microscopy
For whole-mount staining, tissues were fixed with 1% PFA for 1 h
at room temperature. Subsequently, the tissues were washed with
PBS, blocked with the Donkey Immunomix blocking buffer (5%
donkey serum, 0.2% bovine serum albumin, 0.05% sodium azide,
0.3% Triton X-100 in PBS) for 30 min and incubated with primary
antibodies diluted in the blocking buffer overnight at room
temperature or for 2–3 d at +4°C. The primary antibodies were
detected with appropriate secondary antibodies conjugated with
Alexa fluorochromes (Invitrogen) with overnight incubation at
room temperature. The samples were then mounted in mounting
medium containing DAPI (Vector Laboratories). Frozen sections
of the ventral skin (10 mm) were cut and stained as previously
described (Holopainen et al. 2012a).
The following primary antibodies were used: FOXC2 (1:2500)
(Furumoto et al. 1999), GFP (1:1500; Torrey Pines Biolabs,
#TP401), integrin-a9 (1:500; R&D Systems, #AF3827), Ki67
(1:200; Abcam, #ab16667), LYVE1 (1:2000) (Petrova et al. 2004),
2–3 mg/mL PROX1 (1:500; R&D Systems, #AF2727) (Karkkainen
et al. 2004), SMA (1:500; Sigma-Aldrich, #6198), VE-cadherin
(1:100 [BD Biosciences, #555289] and 1:100 [eBioscience, #14-
1441]), VE-cadherin P-Y685 (Orsenigo et al. 2012), and VEGFR3
(1:50; R&D Systems, #AF743).
All whole-mount-stained sampleswere imaged using a confocal
microscope (Zeiss LSM 780, 310: air objectives with numerical
aperture [NA] = 0.45; 340: oil objective with NA = 1.30). Three-
dimensional projections were digitally reconstructed from Z-
stacks with the LSM Zen software (Carl Zeiss). Some images
were stitched from tile-scanned images using the Zen program.
The brightness and contrast of the images were adjusted using
Adobe Photoshop CS5 (Adobe) in accordance with general guide-
lines for scientific image processing.
Quantitative and statistical analyses
Vessel area and length were analyzed using ImageJ (National
Institutes of Health). VE-cadherin P-Y685+ pixels out of total VE-
cadherin+ pixels within lymphatic vessels were quantified using
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the Image Calculator and the ROIManager of ImageJ. Analysis of
FOXC2 and SMA levels in lymphatic vessels were analyzed
similarly. The number of vessel branch points, sprouts, cells per
vessel length, and Ki67+ LECs were counted manually. For
quantification of migration, a square of 1400 mm3 800 mm, with
its longitudinal axis aligned to the ventral midline, was drawn as
indicated in the figures, and the number of vessels within the
square was counted. Zipper junctions were defined as continu-
ous junctions at cell–cell borders, accompanied by elongated cell
shapes; transforming junctions were defined as discontinuous
junctions that align with cell–cell borders, accompanied by
elongated cell shapes; and buttons were defined as discontinuous
junctions that are not parallel to cell–cell borders and are as-
sociated with an oak leaf cell shape (Baluk et al. 2007). Disrupted
junctions were defined as junctions with a jagged shape and
breaks in continuity, associated with a less elongated, but not an
oak leaf, cell shape.
The majority of experiments were repeated two to five times as
indicated in the figure legends with consistent results. A few
experiments were performed once, with N $ 3 per group. For
comparison of means, data were pooled from independently per-
formed repetitive experiments, were analyzed using a two-way
ANOVAwithout interaction, and are presented asmean6 standard
error of mean (SEM). Fisher’s exact test was used to compare
proportions. Holm-Sidak test was used as a post hoc analysis when
more than two groups were compared. Statistical analyses were
carried out with SPSS Statistics (version 20.0) or manually. Statis-
tical significance is indicated in the figures as follows: P < 0.05 (*),
P < 0.01 (**), P < 0.001 (***), and not significant (N.S.).
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